Michael L. Nickerson
National Institutes of Health Bethesda
Dr. Nickerson obtained a Ph.D. in Molecular Medicine from the George Washington University. He has made significant contributions to disease gene identification using positional cloning, including an altered Birt-Hogg-Dubé gene in chromophobe RCC, fumarate hydratase in papillary RCC, the dead-end gene in testicular cancer, and the UBIAD1 gene in Schnyder Corneal Dystrophy. More recently, he has sequenced urologic tumor genomes and identified alterations in TET2 in prostate cancer and the BRCA pathway in bladder and kidney cancer, which have been translated to a clinical trial starting in 2016. He is an active participant in Precision Medicine, ClinVar and the TCGA project.
Urologic Cancer Genetics, Genetics of Bladder Cancer, Genetics of Prostate Cancer, Genetics of Kidney Cancer.